• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...



Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Progress Adequate
Application Number H070005 / PAS001
Date Current Protocol Accepted 02/07/2021
General Study Protocol Parameters
Study Design Retrospective Cohort Study
Data Source New Data Collection
Comparison Group No Control
Analysis Type Descriptive
Study Population Transit. Adolescent A (distinctively) : 18-21 yrs, Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Design Description To evaluate the safety and probable benefit of the AMPLATZER PIVSD Occluder in patients undergoing implantation of the PIVSD Occluder following an acute myocardial infarction. This is multicenter, retrospective non-randomized, observational study.

Study Population Description The intended population for the AMPLATZER™ PIVSD Occluder are patients with post-myocardial infarct muscular ventricular septal defect (VSD) who are not satisfactory surgical candidates. The study will enroll subjects in two cohorts:

First Cohort: All available Emergency and Compassionate PIVSD

Occluder subject data from 2011 to end of 2016.

All subjects belonging to this cohort must have undergone an attempt to close a post-infarct VSD using the AMPLATZER™ PIVSD Occluder.

Second Cohort: The second cohort will be comprised of subjects over the age of 18 who are successfully implanted with a PIVSD Occluder from 2011 onwards. The index procedure must have occurred >6 months prior to enrollment.

The subjects must meet following conditions:

Subject or subject’s legally authorized representative has

provided consent to participate in this study.

Subject’s post-procedure echocardiogram is evaluable and can be sent to the echocardiography core laboratory for residual shunt assessment.

Sample Size First Cohort: All available Emergency and Compassionate PIVSD Occluder subject data from 2011 to the end of 2016.

Second Cohort: A total of 30 subjects who have been successfully implanted with PIVSD occluder and have data for the residual shunt assessed by the echocardiography core laboratory post procedure will be enrolled from up to 50 centers in the US.

Data Collection Cohort 1:

Acute Survival: is defined as survival for at least 24 hours following an attempted PIVSD device implant.

Chronic Survival: is defined as survival for at least 183 days post-procedure.

Technical Success: Technical success occurs when a subject is successfully implanted with a PIVSD device in the ventricular septal defect. An implant attempt occurs when the delivery system is inserted in the subject’s vasculature.

Cohort 2:

Acute Closure: defined as the absence of a residual shunt greater than or equal to 3 mm, and will be assessed based on an echocardiogram obtained immediately after successful deployment of the device and up to 7 days post-procedure.

Chronic Closure: defined as the absence of a residual shunt greater than or equal to 3 mm at 6 months or later (where 6 months is defined as greater than or equal to 150 days)

Chronic Survival: is defined as survival for at least 183 days post-procedure.

Follow-up Visits and Length of Follow-up 6 months
Interim or Final Data Summary
Interim Safety Information The enrollment in cohort 2 is slower than expected, a problem which has persisted from the previous report. The sponsor just made some protocol

changes regarding informed consent and death which they expect will aid in improving enrollment. This is because the revised language is anticipated to enable the enrollment of deceased patients where sites have been unsuccessful at reaching the legally authorized representative to provide informed consent. With this change enrollment is expected to end in Q4 of 2021 with the final report submitted to FDA in Jan. 2022
Actual Number of Patients Enrolled 99 subjects in Cohort 1.

11 subjects have been enrolled in Cohort 2.
Actual Number of Sites Enrolled 19 sites activated for Cohort 2.
Study Strengths & Weaknesses Slower enrollment. The sponsor has revised the protocol aiming to address this.


Report Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
six month report 07/11/2017 07/11/2017 On Time
one year report 01/10/2018 01/10/2018 On Time
18 month report 07/11/2018 07/10/2018 On Time
two year report 01/10/2019 01/10/2019 On Time
three year report 01/10/2020 01/10/2020 On Time
four year report 01/10/2021 01/07/2021 On Time
five year report 01/10/2022    

Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources